克隆性造血、心血管事件及治疗效果:来自五项TIMI随机试验的63700例个体分析
该研究纳入五项随机试验的63700例患者,评估克隆性造血不确定潜能(CHIP)与心血管事件及常用心血管治疗获益的关系。中位随访2.5年,7453例发生至少一次心血管事件;CHIP阳性者总体心血管事件风险无显著升高(aHR=1.07,95%CI 0.99-1.16,P=0.08),但首次心肌梗死风险增加30%(aHR=1.31,95%CI 1.05-1.64,P=0.02),复发心肌梗死风险未增加(aHR=0.94,95%CI 0.79-1.13)。五种试验药物治疗效果在CHIP阳性与阴性者间无显著异质性。
要点
- 在临床试验人群中,CHIP阳性与总体心血管事件风险无显著关联(aHR=1.07,95%CI 0.99-1.16,P=0.08)。
- CHIP阳性者首次心肌梗死风险增加30%(aHR=1.31,95%CI 1.05-1.64,P=0.02),复发心肌梗死风险未增加(aHR=0.94,95%CI 0.79-1.13)。
- 五项试验中所研究的心血管治疗,其疗效在CHIP阳性与阴性者间无显著异质性。
核心结论
- 在临床试验人群中,CHIP与首次冠状动脉事件相关,但与复发冠状动脉事件无关。
- CHIP的存在似乎不能识别从常用心血管治疗中获益更大的患者。
研究设计与样本
- 研究纳入五项测试心血管疾病既定疗法的随机试验中的63700例患者,疗法包括靶向PCSK9、SGLT2、P2Y12和FXa蛋白的治疗。
- 中位随访2.5年,7453例患者发生至少一次心血管事件(心血管死亡、心肌梗死、缺血性卒中或冠状动脉血运重建)。
主要发现
- CHIP阳性患者心血管事件的调整风险比为1.07(95%CI 0.99-1.16,P=0.08),各心血管风险组分的风险估计一致。
- CHIP阳性患者与CHIP阴性患者相比,首次心肌梗死风险增加30%(aHR=1.31,95%CI 1.05-1.64,P=0.02),但复发心肌梗死风险未增加(aHR=0.94,95%CI 0.79-1.13,Pint=0.008)。
- 五项试验中所研究的任何治疗,在CHIP阳性与阴性个体间均未观察到显著的治疗效果异质性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with an increased risk of cardiovascular (CV) disease in the general population. Currently, it is unclear whether this association is observed in large clinical trial cohorts with a high burden of existing CV disease or whether CV therapies can mitigate CHIP-associated CV risk. To address these questions, we studied 63,700 patients from five randomized trials that tested established therapies for CV disease, including treatments targeting the proteins PCSK9, SGLT2, P2Y12 and FXa. During a median follow-up of 2.5 years, 7,453 patients had at least one CV event (CV death, myocardial infarction (MI), ischemic stroke or coronary revascularization). The adjusted hazard ratio (aHR) for CV events for CHIP+ patients was 1.07 (95% CI: 0.99-1.16, P = 0.08), with consistent risk estimates across each component of CV risk. Significant heterogeneity in the risk of MI was observed, such that CHIP+ patients had a 30% increased risk of first MI (aHR = 1.31 (1.05-1.64), P = 0.02) but no increased risk of recurrent MI (aHR = 0.94 (0.79-1.13), Pint = 0.008), as compared to CHIP- patients. Moreover, no significant heterogeneity in treatment effect between individuals with and without CHIP was observed for any of the therapies studied in the five trials. These results indicate that in clinical trial populations, CHIP is associated with incident but not recurrent coronary events and that the presence of CHIP does not appear to identify patients who will derive greater benefit from commonly used CV therapies.
引用
- Marston NA, Pirruccello JP, Melloni GEM, et al. Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials. Nat Med. 2024. PMID: 39107561. doi:10.1038/s41591-024-03188-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。